CEL-SCI Corporation

What they do

CEL-SCI is a late clinical-stage biotechnology company focused on immunotherapies. Its lead candidate, Multikine, is an investigational Phase 3 immunotherapy for newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement and low PD-L1 expression. The company also develops LEAPS (Ligand Epitope Antigen Presentation System) technology, with CEL-4000 as a peptide-based vaccine candidate for rheumatoid arthritis. None of its product candidates have been approved for sale by the FDA or any other regulatory agency.

Revenue drivers

• No commercial revenue — CEL-SCI has no approved products and does not generate revenue from product sales; all projects are under development.
• Multikine (investigational) — Lead candidate for head and neck cancer; not yet commercialized, but Phase 3 data shows potential survival benefit in a target population.
• LEAPS technology — Pre-clinical platform with CEL-4000 for rheumatoid arthritis; not a current revenue source.

Recent performance

For the fiscal year ended September 30, 2025, CEL-SCI reported a net operating loss of approximately $24.8 million, including non-cash expenses of $2.7 million in stock-based compensation and $3.9 million in depreciation. Research and development expenses totaled $15.9 million, down from $18.2 million in 2024, largely due to lower stock compensation. The company had $6.5 million in cash and equivalents as of June 30, 2026, with total assets of $21.4 million and shareholder equity of $11.0 million. Annual net losses have been between $25.4 million and $36.7 million over 2021-2025.

Strategy

CEL-SCI is advancing Multikine toward a confirmatory registration study, with the FDA allowing the company to proceed with a 212-patient randomized controlled trial in the target population. The company plans to conduct this trial as part of a global regulatory approval strategy, including a Breakthrough Medicine Designation application filed with the Saudi Food and Drug Authority in August 2025. CEL-SCI also continues to develop its LEAPS technology, including the CEL-4000 vaccine candidate for rheumatoid arthritis. The company intends to finance operations through equity, convertible notes, loans, and research grants as it continues to incur net operating losses.

Risks

• No regulatory approval — None of CEL-SCI's product candidates are approved for sale, and safety and efficacy are not established; approval from FDA or other agencies is uncertain.
• Cash burn and financing risk — With $6.5 million in cash and annual losses around $25 million, the company will need additional capital, which may not be available on favorable terms.
• Clinical trial reliance — Multikine's future depends on a confirmatory registration study, which may fail to replicate prior results or enroll the required patients.
• Competition — The cancer immunotherapy market is large and competitive; Multikine's unique first-line positioning may not gain adoption against existing therapies.

Outlook

Management expects to continue development of Multikine and other candidates, with ongoing operating losses. The confirmatory registration study is a key near-term milestone, and the company is seeking regulatory paths globally, including in Saudi Arabia. LEAPS remains a pre-clinical focus, but no near-term revenue is anticipated from any product.